Kelhale is an extrafine
beclometasone formulation
With Kelhale, an extrafine beclometasone dipropionate particle formulation, patients can maintain a lower steroid dose than non-extrafine formulations - in line with both NICE and BTS/SIGN guidelines.3-5
Kelhale can also help enable savings to the NHS.8,9
NICE and BTS/SIGN guidelines both recommend using the lowest possible dose of ICS required for effective control of asthma4,5
Kelhale is the least expensive extrafine beclometasone inhaler option for adult patients with asthma9
Kelhale is competitively-priced across its range against non-extrafine beclometasone inhaler options for adult patients with asthma9
Differentiating extrafine and non-extrafine ICS formulations and their benefits10
The Mass Median Aerodynamic Diameter (MMAD) of extrafine beclometasone dipropionate particles is substantially less than that of standard beclometasone dipropionate formulations with respective MMADs of 1.1 and 2.9 µm. Inhalation of such extrafine particles of beclometasone dipropionate results in greater deposition in small airways compared to large particles of beclometasone dipropionate.
A real-world study with over 30,000 patients has shown that beclometasone dipropionate in extrafine particle size produces real-life asthma treatment benefits.
Compared to large particle beclometasone dipropionate, use of the extrafine beclometasone dipropionate resulted in significantly higher:
- Asthma control
- Asthma control plus low short-acting-β2agonist (SABA) use
- Adherence to inhaled corticosteroid therapy
And significantly lower:10
- Rate of respiratory related hospitalisations
- Mean daily SABA dose
Extrafine particle beclometasone dipropionate inhaler use has demonstrated:10
- Improved real-life outcomes measures when managing asthma in primary care
- Greater small airway distribution and inhalation technique tolerance than large-particle beclometasone dipropionate
- Equivalent asthma control and comparable tolerability at approximately half daily dose of large particle beclometasone dipropionate
Extrafine beclometasone products:
Adapted from the eMC Dictionary of Medicines and Devices (dm+d)
and the BTS/SIGN guidelines 2019.5,9
Includes available branded pMDI competitors as listed in BNF June 2024.8
Non-extrafine beclometasone products:
Adapted from the eMC Dictionary of Medicines and Devices (dm+d) and the BTS/SIGN guidelines 20195,9
Includes available branded pMDI competitors as listed in BNF June 2024.8
Qvar is a trademark of Teva Pharmaceuticals. Beclu is a trademark of Lupin Healthcare. Clenil is a trademark of Chiesi Ltd. Soprobec is a trademark of Glenmark Pharmaceuticals.
Adverse events which have been associated with beclometasone dipropionate include: Common (≥1/100 to <1/10); candidiasis of the mouth and throat, hoarseness, pharyngitis and taste disturbances. Uncommon (≥1/1,000 to <1/100); headache, vertigo, tremor, blurred vision, cough, increased asthma symptoms, nausea, urticaria, rash, pruritus, erythema and purpura. Serious hypersensitivity, paradoxical bronchospasm, and systemic effects of inhaled corticosteroids can also occur. For full details of adverse events please consult the SmPC.1,2
Cipla's commitment to sustainable healthcare11
Established in 1935, Cipla is a global pharmaceutical company focused on sustainable growth with a firm commitment to make medicines accessible and available to those in need.12
Cipla has committed to meeting the following environmental targets in its production sites in India, where its respiratory range is manufactured.* By 2025 we aim to achieve:12
- carbon neutrality (for our Scope 1 (fuel-based) and Scope 2 emissions)
- water neutrality
- zero waste to landfill
*India Manufacturing Operations includes manufacturing sites of Cipla Limited and our subsidiaries in India
